da-epoch Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1/2 (1)

Interventional (1)

The First Affiliated Hospital with Nanjing Medical University (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadda-epoch

I am/have/hadprimary central nervous system lymphoma

I am/have/hadchop regimen

I am/have/hadr-chop regimen

I am/have/haddiffuse large b-cell lymphoma

I am/have/hadlymphoma

I am/have/hadepoch-r

I am/have/hadr-da-epoch

I am/have/hadprimary cns lymphoma

I am/have/hadepoch regimen

added new label for I am/have/had

more

I am looking for

I am looking fordoxorubicin

I am looking forcyclophosphamide

I am looking foretoposide

I am looking forlenalidomide

I am looking forvincristine

I am looking forrituximab

I am looking forprednisone

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Previous study showed that lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide in combination with R-DA EPOCH in …

da-epoch

primary central nervous system lymphoma

vincristine

lymphoma

doxorubicin

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.